Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

BI's Praxbind US Approval May Boost Pradaxa Sales

This article was originally published in Scrip

Executive Summary

The FDA on Oct. 16 gave privately held Boehringer Ingelheim GmgH the go-ahead to market its humanized monoclonal antibody fragment Praxbind (idarucizumab) under an accelerated approval as an agent to reverse the blood-thinning effects of the company's highly popular anticoagulant Pradaxa (dabigatran) in emergency surgery or urgent procedures or in situations when there's life-threatening or uncontrolled bleeding.


Related Content

Will Real-World Data Sway Course Of Novel Anticoagulant Market?
Portola Defends AndexXa Antidote Safety, Says Thrombotic Events In Line
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff


Related Companies